Abstracts tagged "juvenile dermatomyositis"

Abstract Number: 2337 • 2017 ACR/ARHP Annual Meeting
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick W Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 2342 • 2017 ACR/ARHP Annual Meeting
Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis
Claire Deakin¹, Elizabeth Rosser¹, Lucy Marshall¹, Meredyth Wilkinson², Aziza Khabbush³, Stefania Simou¹, Georg Otto³, Stefanie Dowle³, Daniel Kelberman³, Simon Yona², Simon Eaton³ and Lucy R Wedderburn¹, ¹Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Although type I interferon (IFN1) and endoplasmic reticulum (ER) stress have been implicated in pathogenesis of juvenile dermatomyositis (JDM), little else is known about…
Abstract Number: 2895 • 2017 ACR/ARHP Annual Meeting
Predictors of Hospitalization, Length of Stay and Costs of Care Among Children with Juvenile Dermatomyositis in the United States
Michael C. Kwa¹, Jonathan I. Silverberg² and Kaveh Ardalan^3,4, ¹Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease that causes significant morbidity and quality of life impairment. Little is known about JDM inpatient burden…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 86 • 2017 Pediatric Rheumatology Symposium
The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies
Takako Miyamae, Takayuki Kishi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Demographics,clinical features,and outcomes among myositis-specific autoantibody (MSA) and myositis-associated autoantibodies (MAAs) subgroups were assessed in children with juvenile idiopathic inflammatory myopathies (JIIM). Methods: MSAs…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…
Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting
Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort
Claire Deakin¹, Raquel Campanilho-Marques², Stefania Simou³, Elena Moraitis⁴, Eleanor Pullenayegum^5,6, Lucy R Wedderburn^4,7,8, Clarissa Pilkington⁹ and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ³Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁵Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
Abstract Number: 1365 • 2016 ACR/ARHP Annual Meeting
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, Nastaran Bayat², Michael Ward³, Adam Huber⁴, Lan Wu¹, Gulnara Mamyrova⁵, Ira Targoff⁶, William Warren-Hicks⁷, Frederick W. Miller², Lisa G. Rider⁸ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁶VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Social and Scientific Systems, Inc., Durham, NC, ⁸Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…
Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Sam Serafi¹, Vladislav Tsaltskan², Anna Yakovleva³, Heidi Sami¹, Frederick W. Miller⁴, Rodolfo Curiel¹, Olcay Y. Jones^1,5 and Lisa G. Rider^1,4, ¹Rheumatology, George Washington University, Washington, DC, ²Internal Medicine, George Washington University, Washington, DC, ³Department of Microbiology, Immunology, and Tropical Medicine., George Washington University, Washington, DC, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁵Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…
Abstract Number: 1371 • 2016 ACR/ARHP Annual Meeting
Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Heather Tory¹, David Zurakowski², Susan Kim³ and CARRA JDM Quality Measures Workgroup, ¹Rheumatology, Connecticut Children's Medical Center, Hartford, CT, ²Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly recognized as important in the care of patients with chronic diseases, such as Juvenile Dermatomyositis (JDM); however,…
Abstract Number: 1372 • 2016 ACR/ARHP Annual Meeting
Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Lisa G. Rider¹, Rohit Aggarwal¹, Sheila Oliveira¹, Rubén J. Cuttica¹, Michel Fischbach², Gary Sterba¹, Karine Brochard², Frank Dressler¹, Patrizia Barone¹, Rubén Burgos-Vargas¹, Elizabeth C. Chalom¹, Marine Desjonqueres¹, Graciela Espada¹, Anders Fasth¹, Stella M. Garay¹, Rose-Marie Herbigneaux¹, Claire Hoyoux¹, Chantal Job-deslandre¹, Frederick W. Miller¹, Jiri Vencovsky¹, Angelo Ravelli³, Alberto Martini³ and Nicolino Ruperto⁴, ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, GENOA, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease characterized by chronic skeletal muscle inflammation with weakness and skin involvement. The Paediatric Rheumatology INternational…
Abstract Number: 2424 • 2016 ACR/ARHP Annual Meeting
Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), a systemic autoimmune vasculopathy, and juvenile idiopathic arthritis (JIA) are representative rheumatic diseases in children. However the pathogenesis of these diseases…
Abstract Number: 2426 • 2016 ACR/ARHP Annual Meeting
Transcriptomic Analysis of Immune Subsets in Juvenile Dermatomyositis before and after Treatment Identifies Novel Pathways Involved in Pathogenesis
Claire Deakin¹, Georg Otto^2,3, Meredyth Wilkinson⁴, Stefanie Dowle^2,3, Stefania Simou⁵, Lucy Marshall⁶, Elizabeth Rosser⁶, Daniel Kelberman^2,3, Lucy R Wedderburn^6,7,8 and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Genetics & Genomic Medicine Programme, UCL Institute of Child Health, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Although proximal muscle weakness and skin rash are the typical features of juvenile dermatomyositis (JDM), little is known about disease pathogenesis, why other features…
Abstract Number: 411 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Juvenile Dermatomyositis: Assessing the Importance of Different Measures to Patients and Families
Heather Tory¹, Ruy Carrasco², Thomas Griffin³, Melissa M. Hazen⁴, Adam M. Huber⁵, Philip Kahn⁶, Angela Byun Robinson⁷, Susan Kim⁸ and The Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Quality Measures Workgroup, ¹Rheumatology, Connecticut Children's Medical Center, Hartford, CT, ²Pediatric Rheumatology, Specially For Children, Austin, TX, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Children's Hospital Boston, Boston, MA, ⁵Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁶Pediatric Rheumatology, New York University, New York, NY, ⁷Pediatrics, Rainbow Babies & Children's Hospital / Case Medical Center, Cleveland, OH, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly important in the care of patients with chronic disease. Involving patients in their own care significantly improves…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].